Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy-Is it prognostic?-a single-center retrospective study.
Sheth V, Potter V, de Lavallade H, Gandhi S, Kulasekararaj A, Krishnamurthy P, Mehra V, Dazzi F, Mufti G, Pagliuca A, Mclornan D, Raj K. Sheth V, et al. Among authors: krishnamurthy p. Blood Cancer J. 2021 Jul 12;11(7):128. doi: 10.1038/s41408-021-00519-y. Blood Cancer J. 2021. PMID: 34253713 Free PMC article.
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ. Krishnamurthy P, et al. Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21. Biol Blood Marrow Transplant. 2013. PMID: 23266740 Free article.
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ. Potter VT, et al. Among authors: krishnamurthy p. Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8. Biol Blood Marrow Transplant. 2014. PMID: 24216184 Free article.
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI).
Feliu J, Potter V, Grimaldi F, Clay J, Floro L, Saha C, Barber L, Orti G, Alnagar AA, Garcia-Muñoz R, Kenyon M, Krishnamurthy P, de Lavallade H, Raj K, McLornan D, Pagliuca A, Mufti GJ. Feliu J, et al. Among authors: krishnamurthy p. Bone Marrow Transplant. 2020 Mar;55(3):562-569. doi: 10.1038/s41409-019-0695-x. Epub 2019 Sep 26. Bone Marrow Transplant. 2020. PMID: 31558789
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C, Ireland R, Czepulkowski B, Pomplun S, Marsh JC, Mufti GJ. Kulasekararaj AG, et al. Among authors: krishnamurthy p. Br J Haematol. 2013 Mar;160(5):660-72. doi: 10.1111/bjh.12203. Epub 2013 Jan 9. Br J Haematol. 2013. PMID: 23297687 Free article.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Dillon R, et al. Among authors: krishnamurthy p. Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959. Blood. 2020. PMID: 31932839 Free PMC article. Clinical Trial.
Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.
Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, Gandhi S, Kuhnl A, Yallop D, Avenoso D, Rice C, Sanderson R, Sarma A, Marsh J, de Lavallade H, Krishnamurthy P, Patten P, Benjamin R, Potter V, Ceesay MM, Mufti GJ, Norton S, Pagliuca A, Galloway J, Kulasekararaj AG. Shah V, et al. Among authors: krishnamurthy p. Br J Haematol. 2020 Sep;190(5):e279-e282. doi: 10.1111/bjh.16935. Epub 2020 Aug 10. Br J Haematol. 2020. PMID: 32526039 Free PMC article. No abstract available.
426 results